Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
FSMEX vs TMED
Shared holdings
18
FSMEX covered by TMED
23.14%
TMED covered by FSMEX
23.14%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
FSMEX (Feb. 28, 2026)
| Security | Weight | |
|---|---|---|
| DANAHER CORP | 13.66% | |
| BOSTON SCIENTIFIC CORP | 12.35% | |
| THERMO FISHER SCIENTIFIC INC | 9.59% | |
| INTUITIVE SURGICAL INC | 8.71% | |
| EDWARDS LIFESCIENCES CORP | 5.61% | |
| STRYKER CORP | 4.95% | |
| ABBOTT LABS | 4.89% | |
| MASIMO CORP | 2.70% | |
| VEEVA SYSTEMS-A | 2.64% | |
| INSULET CORP | 2.44% | |
| IQVIA HOLDINGS INC | 2.21% | |
| WAYSTAR HOLDING CORP | 1.97% | |
| REPLIGEN CORP | 1.91% | |
| BIO-TECHNE CORP | 1.75% | |
| WATERS CORP | 1.58% | |
| Sartorius Stedim Biotech S.A. | 1.55% | |
| BECTON DICKINSON and CO | 1.54% | |
| CARIS LIFE SCIENCES INC | 1.49% | |
| MEDLINE INC-A | 1.36% | |
| IRHYTHM TECHNOLOGIES INC | 1.35% | |
| 10X GENOMICS INC | 1.25% | |
| NATERA INC | 1.14% | |
| PENUMBRA INC | 1.14% | |
| VERACYTE INC | 1.06% | |
| GUARDANT HEALTH INC | 1.06% | |
| AGILENT TECHNOLOGIES INC | 1.00% | |
| GE HEALTHCARE TECHNOLOGIES INC WI | 0.97% | |
| Fidelity Securities Lending Cash Central Fund | 0.93% | |
| KARDIUM SRE D-7 PC PP (REDOMICILE CLOSING AUGUST 2025) | 0.92% | |
| LIFESTANCE HEALTH GROUP INC | 0.72% | |
| KESTRA MEDICAL TECHNOLOGIES INC | 0.64% | |
| Fidelity Cash Central Fund | 0.62% | |
| HEARTFLOW INC | 0.59% | |
| METTLER-TOLEDO INTL INC | 0.48% | |
| ELEMENT BIOSCIENCES INC SER D PC PP | 0.47% | |
| BRUKER CORP | 0.40% | |
| OMADA HEALTH INC | 0.34% | |
| SHOULDER INNOVATIONS INC(180 Day Lockup) | 0.33% | |
| FREENOME HOLDINGS INC SER D PC PP | 0.32% | |
| 10X GENOMICS INC CL B 144A | 0.25% | |
| ALEDADE INC SER F PC PP | 0.17% | |
| GALVANIZE THERAPEUTICS SER C-1 PC PERP PP | 0.17% | |
| ICU MEDICAL INC | 0.17% | |
| MANUS BIO INC SER ONE-6 PC PP | 0.16% | |
| DNA SCRIPT SAS SER C PC PP | 0.14% | |
| ASIMOV INC SER B PC PP | 0.07% | |
| DOXIMITY INC-A | 0.07% | |
| SALUDA MEDICAL INC WT PP | 0.06% | |
| DMED BIOPHARMACEUTICAL CO LTD SER C PC PP | 0.05% | |
| SALUDA MEDICAL INC CDI | 0.04% |
TMED (March 31, 2026)
| Security | Weight | |
|---|---|---|
| LILLY ELI and CO | 14.43% | |
| UNITEDHEALTH GRP | 6.52% | |
| THERMO FISHER SCIENTIFIC INC | 4.58% | |
| GILEAD SCIENCES INC | 4.13% | |
| ABBOTT LABS | 3.90% | |
| DANAHER CORP | 2.72% | |
| MEDTRONIC PLC | 2.24% | |
| ALNYLAM PHARMACEUTICALS INC | 2.05% | |
| STRYKER CORP | 2.00% | |
| DYNE THERAPEUTICS INC | 1.87% | |
| WATERS CORP | 1.75% | |
| BECTON DICKINSON and CO | 1.70% | |
| AGILENT TECHNOLOGIES INC | 1.68% | |
| ELANCO ANIMAL HEALTH INC | 1.58% | |
| HUMANA INC | 1.56% | |
| CYTOKINETICS INC | 1.53% | |
| WEST PHARMACEUTICAL SVCS INC | 1.48% | |
| BOSTON SCIENTIFIC CORP | 1.46% | |
| Ascendis Pharma A/S | 1.39% | |
| BIOGEN INC | 1.25% | |
| VAXCYTE INC | 1.18% | |
| IMMUNOME INC | 1.15% | |
| METTLER-TOLEDO INTL INC | 1.10% | |
| CENCORA INC | 1.06% | |
| APELLIS PHARMACEUTICALS INC | 1.02% | |
| REGENERON PHARMACEUTICALS INC | 1.01% | |
| DEXCOM INC | 1.00% | |
| CVS HEALTH CORP | 0.95% | |
| MOONLAKE IMMUNOTHERAPEUTICS | 0.89% | |
| INSULET CORP | 0.83% | |
| ADAPTIVE BIOTECHNOLOGIES CORP | 0.82% | |
| BICARA THERAPEUTICS INC | 0.81% | |
| BIONTECH SE ADR | 0.80% | |
| IMMATICS NV COMMON STOCK | 0.79% | |
| REPLIGEN CORP | 0.79% | |
| COOPER COS INC | 0.77% | |
| SHATTUCK LABS INC | 0.76% | |
| IDEXX LABS INC | 0.74% | |
| XENON PHARMACEUTICALS INC | 0.73% | |
| SAREPTA THERAPEUTICS INC | 0.73% | |
| BRISTOL-MYERS SQUIBB CO | 0.73% | |
| MOLINA HEALTHCARE INC | 0.71% | |
| APOGEE THERAPEUTICS INC | 0.69% | |
| CG ONCOLOGY INC | 0.68% | |
| AGIOS PHARMACEUTICALS INC | 0.65% | |
| INCYTE CORP | 0.65% | |
| KYMERA THERAPEUTICS INC | 0.61% | |
| OPTION | 0.58% | |
| CABALETTA BIO INC | 0.58% | |
| ALIGN TECHNOLOGY INC | 0.53% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.